Phase III Trial Opens: AI-Guided Anti-HER2 Therapy vs Standard PCbHP in Early Breast Cancer — What Clinicians Need to Know

References

1. 1.Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., ... & Senkus, E. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 30(8), 1194-1220. https://doi.org/10.1093/annonc/mdz173
2. 2.Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., ... & von Minckwitz, G. (2014). Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. The Lancet, 384(9938), 164-172. https://doi.org/10.1016/S0140-6736(13)62422-8
3. 3.Fudan University. (2024). Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy: A Randomized, Controlled, Open-Label, Multicenter Phase III Clinical Study. ClinicalTrials.gov. NCT07528716. https://clinicaltrials.gov/study/NCT07528716
4. 4.Gianni, L., Pienkowski, T., Im, Y. H., Tseng, L. M., Liu, M. C., Lluch, A., ... & Valagussa, P. (2016). 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. The Lancet Oncology, 17(6), 791-800. https://doi.org/10.1016/S1470-2045(15)00544-2
5. 5.Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021). Breast cancer. Nature Reviews Disease Primers, 7(1), 1-22. https://doi.org/10.1038/s41572-021-00301-0
6. 6.Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S. B., Tamura, K., ... & Tsurutani, J. (2020). Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. New England Journal of Medicine, 382(7), 610-621. https://doi.org/10.1056/NEJMoa1914510
7. 7.Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., ... & Crown, J. (2011). Adjuvant trastuzumab in HER2-positive breast cancer. New England Journal of Medicine, 365(14), 1273-1283. https://doi.org/10.1056/NEJMoa0910383